查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961451

十二指腸潰瘍治療市場－全球產業規模、佔有率、趨勢、機會、預測：治療方法、給藥途徑、通路、區域及競爭格局，2021-2031年

Duodenal Ulcer Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Route Of Administration, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球十二指腸潰瘍治療市場預計將從 2025 年的 53.1 億美元成長到 2031 年的 68.5 億美元，複合年成長率為 4.34%。

該市場涵蓋質子幫浦阻斷劑、抗生素和鉀離子競爭性酸分泌抑制劑等治療藥物，旨在修復近端小腸黏膜損傷。主要成長要素包括非類固醇消炎劑(NSAIDs) 的廣泛應用以及全球範圍內需要持續藥物治療的細菌感染疾病負擔。特別是，美國胃腸病學會 (AGA) 2024 年報告指出，成人幽門螺旋桿菌感染的粗略盛行率已達 43.9%，證實存在一個穩定的患者群體，需要根除治療以預防潰瘍復發和併發症。

市場概覽
預測期 2027-2031
市場規模：2025年 53.1億美元
市場規模：2031年 68.5億美元
複合年成長率：2026-2031年 4.34%
成長最快的細分市場 質子幫浦阻斷劑
最大的市場 北美洲

儘管需求指標強勁，市場仍面臨一個重大障礙：抗生素抗藥性日益增強。這降低了標準治療通訊協定的有效性。抗藥性的上升迫使臨床醫生依賴更複雜的補救性治療，使根除疾病變得更加困難。因此，廣泛有效的疾病管理面臨許多挑戰，並可能限制第一線標準藥物的持續使用。

市場促進因素

日益成長的脆弱老年人口正成為全球十二指腸潰瘍治療市場的主要推動力，顯著改變了患者群體結構，並持續推動對治療方案的需求。隨著老齡化，胃黏膜的天然防禦能力下降，使老年人更容易受到胃酸和幽門螺旋桿菌感染的損害。老年人常見的合併症，例如關節炎，進一步加劇了這種易感性，並導致他們長期服用非類固醇消炎劑（NSAIDs），而NSAIDs正是潰瘍形成的主要風險因素。根據聯合國人口基金（UNFPA）的數據，截至2024年6月，65歲及以上人口將佔世界人口的10.3%，需要積極抑酸或根除治療以預防出血和穿孔等併發症的高風險患者群體正在迅速擴大。

同時，新型治療藥物的研發正在重振市場。這些藥物克服了傳統質子幫浦阻斷劑（PPI）的局限性，尤其是在應對抗生素抗藥性等問題方面。藥廠正積極推出鉀離子競爭性酸分泌抑制劑（P-CAB），與傳統藥物相比，這類藥物起效較快，在酸性環境下穩定性較佳。此類藥物的商業性成功顯而易見；2024年5月，武田藥品工業株式會社宣布，其P-CAB製劑「Takecab/Bocinti」在截至2024年3月的會計年度銷售額達到1185億日元，市場滲透率很高。此外，製造商正將目光投向新興市場，以滿足尚未被滿足的醫療需求。例如，2024年8月，大隈製藥將其新藥fexprazan拓展至拉丁美洲市場，目標市場是墨西哥、智利和厄瓜多爾價值3億美元的抗潰瘍藥物市場。這些創新提供了有效的替代方案，並在抗藥性挑戰下保持了市場價值。

市場挑戰

抗生素抗藥性日益嚴重的是全球十二指腸潰瘍治療市場面臨的一大障礙，從根本上削弱了標準藥物治療方案的可靠性。傳統的第一線療法，例如質子幫浦阻斷劑合併克拉黴素或甲硝唑，其臨床療效已顯著下降，尤其是在幽門螺旋桿菌等細菌菌株對主要抗生素產生強抗藥性的情況下。這種療效的下降迫使醫療機構放棄高效的高劑量治療方案，轉而採用更複雜、更長期的替代療法。因此，藥物庫存周轉率變得難以預測，現有藥物組合的商業性可行性也受到威脅，因為臨床醫生在未進行昂貴的藥敏試驗之前，不願輕易開立標準抗生素療程。

近期臨床數據凸顯了這些市場障礙的嚴重性，尤其強調了治療失敗的規模。根據美國胃腸病學會 (ACG) 2024 年的報告，在美國所有監測區域，克拉黴素的抗藥性率已超過 20%。這項數據表明，相當一部分目標患者群體對最常用的經驗性治療不再有效。如此高的抗藥性造成了不穩定的市場環境，無法保證標準藥物的持續使用，阻礙了十二指腸潰瘍治療領域的整體進展。

市場趨勢

幽門螺旋桿菌根除療法中固定劑量複方製劑的普及正在改變市場格局，有效解決了患者難以堅持複雜多藥聯合治療的重大難題。為了應對聯合治療克拉黴素三重療法日益嚴重的抗藥性問題，製藥公司推出了一系列包含抗生素和抑酸劑的複方膠囊，旨在簡化給藥方案並提高殺菌效果。隨著支付方逐漸認知到簡化給藥方案有助於避免治療失敗和後續補救治療，這一趨勢正獲得商業性的成功。例如，2024年8月，Redhill BioPharma宣布其基於利福布汀的固定劑量組合藥物Talicia已將處方箋覆蓋範圍擴大到美國約2500萬受益人，這表明市場正明顯轉向簡化的、以抗藥性為重點的根除通訊協定。

同時，在治療潰瘍相關併發症（例如上消化道出血）方面，微創內視鏡治療性介入正顯著興起。先進的止血技術，例如內視鏡夾和止血粉，正在取代傳統的外科手術方法，提高治療的精確度，並降低高風險出血性潰瘍的併發症。新一代可視化系統的普及提高了對這些病變的檢測和治療能力，從而推動了醫療設備行業的顯著收入成長。根據Olympus Corporation2024年5月發布的公告，EVIS X1內視鏡系統的推出使其在北美的胃腸內視鏡業務同比成長了20%，凸顯了臨床對先進治療視覺化平台日益成長的需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：十二指腸潰瘍治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（質子幫浦阻斷劑、H2受體拮抗劑、抗生素等）
    • 給藥途徑（口服、注射）
    • 分銷通路（零售藥局、醫院藥局、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美十二指腸潰瘍治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲十二指腸潰瘍治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區十二指腸潰瘍治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲十二指腸潰瘍治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲十二指腸潰瘍治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球十二指腸潰瘍治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Takeda
  • AstraZeneca
  • Pfizer
  • GlaxoSmithKline
  • Novartis
  • Bayer
  • Sanofi
  • Johnson & Johnson
  • Sun Pharma
  • Cipla

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25081

The Global Duodenal Ulcer Treatment Market is projected to expand from USD 5.31 Billion in 2025 to USD 6.85 Billion by 2031, reflecting a CAGR of 4.34%. This market encompasses therapeutic agents like proton pump inhibitors, antibiotics, and potassium-competitive acid blockers designed to heal mucosal defects in the proximal small intestine. Key growth drivers include the widespread use of nonsteroidal anti-inflammatory drugs and the enduring global burden of bacterial infections requiring ongoing pharmaceutical management. Notably, the American Gastroenterological Association reported in 2024 that the crude global prevalence of Helicobacter pylori infection among adults stood at 43.9%, ensuring a consistent patient base needing eradication therapy to avert ulcer recurrence and complications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.31 Billion
Market Size 2031USD 6.85 Billion
CAGR 2026-20314.34%
Fastest Growing SegmentProton Pump Inhibitors
Largest MarketNorth America

Despite these robust demand indicators, the market faces a substantial obstacle in the form of increasing antimicrobial resistance, which diminishes the effectiveness of standard treatment protocols. This rising resistance compels clinicians to resort to more intricate salvage therapies and complicates successful eradication efforts. Consequently, this creates a significant hurdle to effective disease management on a broad scale and potentially restricts the consistent utilization of standard first-line pharmaceutical options.

Market Driver

The expansion of the vulnerable geriatric population acts as a primary catalyst for the Global Duodenal Ulcer Treatment Market, significantly reshaping patient demographics and fueling sustained demand for therapeutic solutions. As people age, natural defenses in the gastric mucosa weaken, rendering the elderly far more prone to damage from gastric acid and Helicobacter pylori infections. This susceptibility is further aggravated by the prevalence of comorbidities like arthritis in older adults, necessitating chronic use of non-steroidal anti-inflammatory drugs (NSAIDs), which are major risk factors for ulceration. According to the United Nations Population Fund in June 2024, the global proportion of individuals aged 65 and older rose to 10.3%, creating a rapidly expanding base of high-risk patients requiring potent acid-suppression and eradication therapies to prevent complications such as bleeding or perforation.

Concurrently, the development of novel therapeutic agents is revitalizing the market by overcoming the limitations of traditional proton pump inhibitors (PPIs), especially regarding antibiotic resistance. Pharmaceutical firms are aggressively launching potassium-competitive acid blockers (P-CABs), which provide faster onset and superior stability in acidic conditions compared to conventional options. The commercial viability of this class is clear; Takeda Pharmaceutical Company Limited reported in May 2024 that sales of its P-CAB, Takecab/Vocinti, hit 118.5 billion JPY for the fiscal year ending March 31, 2024, showing strong adoption. Additionally, manufacturers are targeting emerging markets to address unmet needs; for instance, Daewoong Pharmaceutical expanded its novel agent Fexuprazan into Latin America in August 2024, aiming at an anti-ulcer market worth $300 million across Mexico, Chile, and Ecuador. These innovations offer effective salvage alternatives, maintaining market value despite resistance challenges.

Market Challenge

The escalating incidence of antimicrobial resistance poses a significant barrier to the Global Duodenal Ulcer Treatment Market by fundamentally compromising the reliability of standard pharmaceutical regimens. As bacterial strains, specifically Helicobacter pylori, build strong immunity to crucial antibiotics, the clinical effectiveness of traditional first-line therapies-usually involving proton pump inhibitors alongside clarithromycin or metronidazole-drops markedly. This decline in success rates obliges healthcare providers to move away from streamlined, high-volume prescription patterns toward more complicated, extended-duration salvage therapies. As a result, pharmaceutical inventory turnover becomes unpredictable, and the commercial viability of established drug combinations is jeopardized as clinicians become reluctant to prescribe standard antibiotic packs without costly susceptibility testing.

The gravity of this market impediment is highlighted by recent clinical data emphasizing the magnitude of therapeutic failure. According to the American College of Gastroenterology in 2024, resistance rates to clarithromycin were confirmed to reach or exceed 20 percent across all monitored regions in the United States. This statistic reveals that a significant portion of the target patient population is now unresponsive to the most frequent empiric treatments. Such elevated resistance levels generate a volatile market atmosphere where the consistent use of standard pharmaceutical products cannot be guaranteed, thereby stalling momentum within the broader duodenal ulcer treatment sector.

Market Trends

The proliferation of fixed-dose combination kits for H. pylori eradication is transforming the market by tackling the critical problem of patient non-adherence to complex multi-drug regimens. With resistance to standard clarithromycin-based triple therapies increasing, pharmaceutical developers are launching all-in-one capsules that merge antibiotics with acid suppressants to simplify dosing schedules and boost bactericidal potency. This trend is gaining commercial momentum as payers acknowledge the benefits of streamlined administration in averting treatment failure and subsequent salvage needs. For instance, RedHill Biopharma announced in August 2024 that its rifabutin-based fixed-dose combination, Talicia, achieved expanded formulary coverage for roughly 25 million lives in the United States, signaling a distinct market shift toward simplified, resistance-oriented eradication protocols.

Simultaneously, there is a marked shift toward minimally invasive endoscopic therapeutic interventions for managing ulcer-related complications like upper gastrointestinal bleeding. Advanced hemostatic technologies, such as through-the-scope clips and hemostatic powders, are superseding traditional surgical methods, enabling clinicians to treat high-risk bleeding ulcers with enhanced precision and reduced morbidity. The widespread implementation of next-generation visualization systems improves the detection and treatment of these lesions, driving substantial revenue growth in the device sector. According to Olympus Corporation in May 2024, its GI Endoscopy business in North America expanded by 20% year-over-year following the launch of the EVIS X1 endoscopy system, highlighting the growing demand for advanced therapeutic visualization platforms in clinical settings.

Key Market Players

  • Takeda
  • AstraZeneca
  • Pfizer
  • GlaxoSmithKline
  • Novartis
  • Bayer
  • Sanofi
  • Johnson & Johnson
  • Sun Pharma
  • Cipla

Report Scope

In this report, the Global Duodenal Ulcer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Duodenal Ulcer Treatment Market, By Treatment

  • Proton Pump Inhibitors
  • H2 Antagonists
  • Antibiotics
  • Other

Duodenal Ulcer Treatment Market, By Route Of Administration

  • Oral
  • Parenteral

Duodenal Ulcer Treatment Market, By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Other

Duodenal Ulcer Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Duodenal Ulcer Treatment Market.

Available Customizations:

Global Duodenal Ulcer Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Duodenal Ulcer Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Proton Pump Inhibitors, H2 Antagonists, Antibiotics, Other)
    • 5.2.2. By Route Of Administration (Oral, Parenteral)
    • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Other)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Duodenal Ulcer Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By Route Of Administration
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Duodenal Ulcer Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By Route Of Administration
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Duodenal Ulcer Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By Route Of Administration
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Duodenal Ulcer Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By Route Of Administration
        • 6.3.3.2.3. By Distribution Channel

7. Europe Duodenal Ulcer Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By Route Of Administration
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Duodenal Ulcer Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By Route Of Administration
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France Duodenal Ulcer Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By Route Of Administration
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Duodenal Ulcer Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By Route Of Administration
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Duodenal Ulcer Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By Route Of Administration
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Duodenal Ulcer Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By Route Of Administration
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Duodenal Ulcer Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By Route Of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Duodenal Ulcer Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By Route Of Administration
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Duodenal Ulcer Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By Route Of Administration
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Duodenal Ulcer Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By Route Of Administration
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Duodenal Ulcer Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By Route Of Administration
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Duodenal Ulcer Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By Route Of Administration
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Duodenal Ulcer Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By Route Of Administration
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Duodenal Ulcer Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By Route Of Administration
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE Duodenal Ulcer Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By Route Of Administration
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa Duodenal Ulcer Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By Route Of Administration
        • 9.3.3.2.3. By Distribution Channel

10. South America Duodenal Ulcer Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By Route Of Administration
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Duodenal Ulcer Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By Route Of Administration
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia Duodenal Ulcer Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By Route Of Administration
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina Duodenal Ulcer Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By Route Of Administration
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Duodenal Ulcer Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Takeda
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AstraZeneca
  • 15.3. Pfizer
  • 15.4. GlaxoSmithKline
  • 15.5. Novartis
  • 15.6. Bayer
  • 15.7. Sanofi
  • 15.8. Johnson & Johnson
  • 15.9. Sun Pharma
  • 15.10. Cipla

16. Strategic Recommendations

17. About Us & Disclaimer